Biolinq Incorporated's novel microsensor, designed for autonomous time-in-range monitoring, has received FDA clearance, signaling a potential expansion in continuous glucose monitoring technologies.
Biolinq Incorporated has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biolinq Shine Autonomous Time-in-Range Microsensor. The decision, dated September 18, 2026, deems the device substantially equivalent for its intended use, classified under product code SFU (Continuous Glucose Monitor, implanted, short-term).
The clearance positions the Biolinq Shine microsensor within the Class II regulatory category, governed by regulation number 862.1359, pertaining to glucose test systems. The review process was a Traditional 510(k) and involved the Clinical Chemistry advisory committee.
Device Function and Market Context
The Biolinq Shine Autonomous Time-in-Range Microsensor is designed to provide continuous, autonomous monitoring of glucose levels, with a specific focus on 'time-in-range' metrics. This metric is increasingly recognized as a crucial indicator for glycemic control beyond traditional HbA1c measurements, offering a more dynamic view of glucose fluctuations throughout the day.
While details on the specific operational parameters, user interface, and integration capabilities of the Biolinq Shine system are not yet publicly disclosed, the 'autonomous' descriptor suggests a design aimed at minimizing user intervention once deployed. The market for continuous glucose monitoring (CGM) devices has seen significant growth and innovation, driven by improved accuracy, wearability, and data insights for individuals with diabetes.
The FDA's 'substantially equivalent' determination allows Biolinq to market its device, signaling confidence in its safety and effectiveness compared to existing legally marketed predicate devices.
Future Implications
This regulatory milestone clears the path for Biolinq to potentially introduce a new form factor or operational paradigm into the CGM space. The emphasis on 'microsensor' indicates a focus on miniaturization, which could improve user comfort and discretion.
Commercial availability, pricing, and specific clinical claims beyond the scope of this 510(k) summary are anticipated to be disclosed by Biolinq Incorporated as they prepare for market entry. The competitive landscape for glucose monitoring continues to evolve rapidly, with ongoing advancements in sensor technology, data analytics, and integration with digital health platforms.
